Can we identify who gets benefit or harm from mycophenolate mofetil in systemic lupus erythematosus? A systematic review

被引:6
|
作者
Mendoza-Pinto, Claudia [1 ]
Pirone, Carmelo [2 ]
van der Windt, Danielle A. [3 ]
Parker, Ben [4 ,5 ]
Bruce, Ian N. [4 ,6 ]
机构
[1] Mexican Inst Social Secur, Reg Gen Hosp CIBIOR 36, Syst Autoimmune Dis Res Unit, Puebla, Mexico
[2] Sapienza Univ Rome, Dept Internal Med, Med Specialties Rheumatol Unit, Rome, Italy
[3] Keele Univ, Arthrit Res UK Primary Care Ctr, Res Inst Primary Care & Hlth Sci, Keele, Staffs, England
[4] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, NIHR Manchester Musculoskeletal Biomed Res Unit, Oxford Rd, Manchester, Lancs, England
[5] Univ Manchester, Manchester Acad Hlth Sci Ctr, Ctr Musculoskeletal Res, Fac Biol Med & Hlth, Manchester, Lancs, England
[6] Univ Manchester, Manchester Acad Hlth Sci Ctr, Arthrit Res UK Ctr Epidemiol, Fac Biol Med & Hlth, Oxford Rd, Manchester, Lancs, England
基金
英国医学研究理事会; 英国惠康基金;
关键词
Systemic lupus erythematosus; Mycophenolate mofetil; Systematic review; Prognosis; INTRAVENOUS CYCLOPHOSPHAMIDE; MAINTENANCE THERAPY; NEPHRITIS TREATMENT; INDUCTION TREATMENT; POLYMORPHISMS; DISEASE; ACID; PHARMACOKINETICS; AZATHIOPRINE; ASSOCIATION;
D O I
10.1016/j.semarthrit.2017.01.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: We aimed to summarize the evidence examining factors that predict differential response to mycophenolate mofetil (MMF) in systemic lupus erythematosus (SLE). Methods: Systematic searches of randomized clinical trials (RCT) to identify predictors of the effects of MMF (moderators), and cohort studies to explore prognostic factors associated with MMF outcomes (response, relapse, or adverse events) were performed. Two reviewers independently assessed the methodological quality of RCTs using the Cochrane Collaboration risk of bias tool and cohort studies using the QUality In Prognosis Studies tool. The quality of subgroup analysis, providing evidence for moderation, was evaluated. The Grading of Recommendations Assessment, Development, and Evaluation working group approach summarized the quality of evidence (QoE), considering the risk of bias, imprecision, inconsistency, indirectness, and publication bias. Results: From 26 studies (13 from 7 RCTs and 13 cohort studies) we found low QoE evidence for Black/Hispanic race/ethnicity predicting better renal responses to MMF in lupus nephritis (LN) from one RCT. There was low QoE evidence from cohort studies that a higher baseline creatinine and membranous features on renal biopsy were associated with poorer responses in LN. There was very low QoE for other moderators or prognostic factors associated with MMF treatment outcomes. QoE from RCTs was affected by exploratory or insufficient evidence from subgroup analysis and in both study types high risk of bias, indirectness and imprecision also affected QoE. Conclusions: In SLE, evidence for predictors of response to MMF is limited and none can be recommended for use in routine clinical practice. Specific studies of predictors measured at baseline and during treatment are needed with a priori hypotheses based on preliminary evidence to date and with sufficient power to determine which factors can be employed in clinical decision making. (C) 2017 The Authors. Published by Elsevier HS Journals, Inc.
引用
收藏
页码:65 / 78
页数:14
相关论文
共 50 条
  • [41] Indication for cataract surgery. Do we have evidence of who will benefit from surgery? A systematic review and meta-analysis
    Kessel, Line
    Andresen, Jens
    Erngaard, Ditte
    Flesner, Per
    Tendal, Britta
    Hjortdal, Jesper
    ACTA OPHTHALMOLOGICA, 2016, 94 (01) : 10 - 20
  • [42] Can we identify those patients who will benefit from prostate-sparing surgery? Predictive factors for invasive prostatic involvement by transitional cell carcinoma
    Arce, Jacob
    Gaya, Josep M.
    Huguet, Jorge
    Rodriguez, Oscar
    Palou, Joan
    Villavicencio, Humberto
    CANADIAN JOURNAL OF UROLOGY, 2011, 18 (01) : 5529 - 5536
  • [43] How can we accurately measure disease activity during pregnancy in systemic lupus erythematosus? New insights from the BILAG-2004 Pregnancy Index
    Ali, Sasha
    Garcia, Carmen
    Fasano, Serena
    Wincup, Chris
    RHEUMATOLOGY ADVANCES IN PRACTICE, 2022, 7 (01)
  • [44] Serum procalcitonin and C-reactive protein levels as diagnostic markers for distinguishing bacterial infections from lupus flares in systemic lupus erythematosus: A systematic review and meta-analysis
    Chen, Yuting
    Shen, Jiran
    Yang, Hui
    Xu, Shanshan
    Ma, Yubo
    Pan, Faming
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 101
  • [45] Re: Can we identify those patients who will benefit from prostate-sparing surgery? Predictive factors for invasive prostatic involvement by transitional cell carcinoma COMMENT
    Djavan, Bob
    CANADIAN JOURNAL OF UROLOGY, 2011, 18 (01) : 5536 - 5536
  • [46] How can we identify HCV genotype 1 patients who may benefit from an extended treatment duration with peginterferon α-2a (40kD) plus RBV?
    Sanchez-Tapias, J. M.
    Ferenci, R.
    Diago, M.
    Romero-Gomez, M.
    Zeuzem, S.
    Berg, T.
    JOURNAL OF HEPATOLOGY, 2007, 46 : S242 - S242
  • [47] Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016 (vol 76, pg 2009, 2017)
    Tektonidou, M. G.
    Lewandowski, L. B.
    Hu, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (03) : 472 - 472
  • [48] Can we identify how programmes aimed at promoting self-management in musculoskeletal pain work and who benefits? A systematic review of sub-group analysis within RCTs
    Miles, Clare L.
    Pincus, Tamar
    Carnes, Dawn
    Homer, Kate E.
    Taylor, Stephanie J. C.
    Bremner, Stephen A.
    Rahman, Anisur
    Underwood, Martin
    EUROPEAN JOURNAL OF PAIN, 2011, 15 (08) : 775.e1 - 775.e11
  • [49] Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?
    Baker, Kenneth F.
    Isaacs, John D.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (02) : 175 - 187
  • [50] Additional Improvements in Clinical Response From Adjuvant Biologic Response Modifiers in Adults With Moderate to Severe Systemic Lupus Erythematosus Despite Immunosuppressive Agents: A Systematic Review and Meta-analysis
    Shamliyan, Tatyana A.
    Dospinescu, Paula
    CLINICAL THERAPEUTICS, 2017, 39 (07) : 1479 - 1506